245,707 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Great Lakes Advisors LLC

Great Lakes Advisors LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 245,707 shares of the company’s stock, valued at approximately $6,047,000.

Several other large investors have also bought and sold shares of ELAN. BlackRock Inc. purchased a new position in shares of Elanco Animal Health during the 2nd quarter worth approximately $1,202,198,000. UBS Group AG lifted its stake in shares of Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after purchasing an additional 5,961,457 shares during the period. Sei Investments Co. lifted its stake in shares of Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after purchasing an additional 4,975,721 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after purchasing an additional 3,717,404 shares in the last quarter. Finally, Invesco Ltd. boosted its position in shares of Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after purchasing an additional 3,690,735 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 31st. TD Cowen raised their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Citigroup lifted their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Finally, KeyCorp lifted their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $24.47 on Thursday. The company has a market capitalization of $12.22 billion, a price-to-earnings ratio of -59.67, a price-to-earnings-growth ratio of 1.42 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98. The company’s 50-day moving average is $24.57 and its 200 day moving average is $24.01.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Insider Activity

In other Elanco Animal Health news, Director Michael J. Harrington acquired 5,000 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average cost of $21.82 per share, with a total value of $109,100.00. Following the transaction, the director owned 131,451 shares of the company’s stock, valued at $2,868,260.82. The trade was a 3.95% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Robert M. Vanhimbergen bought 4,200 shares of the business’s stock in a transaction on Friday, August 7th. The shares were acquired at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the completion of the purchase, the chief financial officer owned 137,516 shares in the company, valued at approximately $3,173,869.28. The trade was a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 23,198 shares of company stock worth $537,109 over the last three months. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.